ENGENE HOLDINGS INC 已成功获得一笔总额高达1亿美元的融资,这笔资金将专项用于其膀胱癌治疗药物Detalimogene的后续开发及商业化进程。此次融资为Detalimogene项目的推进提供了强有力的资金保障,有望加速该创新疗法的研发与市场应用。
ENGENE HOLDINGS INC 已成功获得一笔总额高达1亿美元的融资,这笔资金将专项用于其膀胱癌治疗药物Detalimogene的后续开发及商业化进程。此次融资为Detalimogene项目的推进提供了强有力的资金保障,有望加速该创新疗法的研发与市场应用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.